Emmaus Life Sciences Inc EMMA
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 70.19M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 33
- Website
- https://www.emmausmedical.com
Valuation
|
Metric
|
EMMA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.26 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EMMA
|
|---|---|
Quick Ratio | 0.05 |
Current Ratio | 0.09 |
Interest Coverage | 0.28 |
Quick Ratio
EMMA
Profitability
|
Metric
|
EMMA
|
|---|---|
Return on Assets (Normalized) | −22.42% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
EMMA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Vk!p&xN | LOCK|&#G& | $128B | |||
| Moderna Inc
MRNA
| LOCK|kv<>^&B | LOCK|l? | $81B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Kk%KRY< | LOCK|wR$! | $75B | |||
| argenx SE ADR
ARGX
| LOCK|<!l>!H | LOCK|@@ | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@Vc$X! | LOCK|wr | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|J%NXFc | LOCK|^%#w | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Q&Jt$cfk | LOCK|?#NpS | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|#tv!&>J | LOCK|^#q | $25B | |||
| Incyte Corp
INCY
| LOCK|#d>pdwP | LOCK|Z$C | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@Q^v<s | LOCK|JT | $15B |
United States